Stock Taper
SCREENER COMPARE ANY 2 STOCKS
VTGN
VISTAGEN THERAPEUTICS, INC.
NASDAQ
$0.25
▼ DOWN 1.60% (-0.00)

KEY STATISTICS

Market Cap$11.22 M
52w High$5.14
52w Low$0.20
Dividend Yield—
Frequency—
P/E-0.15
Volume448.95K
Shares Out.44.38M

COMPANY

LEADERSHIP

Shawn K. Singh
CHIEF EXECUTIVE
Shawn K. Singh

COMPENSATION 2026

Salary$650,000
Stock Awards$0
Incentive Plan Pay$0
All Other Comp.$0
Total$1,212,560

ABOUT

SECTOR
Healthcare
WENT PUBLIC
June 21, 2011
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
41

PRICE TARGET

Target High$1.00
Target Low$0.90
Target Median$0.95
Target Consensus$0.95

UPCOMING EARNINGS

DateNov 12, 2026
DayThursday
Rev. Est.$500.00K
NOV
12
THU

SPLIT RECORD

DATETYPERATIO
2023-06-07Reverse1:30
2014-08-18Reverse1:20
2014-08-14Reverse1:20

PRICE

$0.25 ▼ DOWN 1.60% (−$0.00)
OVERLAYS
$0.25$0.25$0.26$0.269:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM0.25

About VistaGen Therapeutics, Inc.

https://www.vistagen.com ↗

VistaGen Therapeutics is a clinical-stage biopharma developing CNS medicines like PH94B for anxiety, PH10 for depression, and AV-101 for various neurological and psychiatric conditions.

INDUSTRY

Biotechnology

A PRODUCT VISTAGEN THERAPEUTICS, INC. IS KNOWN FOR

Fasedienol (PH94B)
Fasedienol (PH94B)

Fasedienol is a Phase 3 investigational nasal spray targeting social anxiety disorder by modulating fear-related neural circuits without systemic effects, offering a potential on-demand anxiety treatment.

COMPETITORS

COMPETITOR
ATAI COMPARE
AXSM COMPARE

Revenue by Products

IconPRODUCTQ2-2023Q3-2023Q4-2023Q1-2024
License$1.42M $711.3K ▼$176K ▼$177.6K ▲

ETFS HOLDING THIS STOCK

ETFS HOLDING
12
LISTED HERE
2
RANKED BY POSITION SIZE
VTS.AX
0.00% · 1.2M
PSIL
0.24% · 525.1K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
46.89%
HOLDERS
88
TOP 12 OF 88 · RANKED BY POSITION SIZE
Janus Henderson Group Plc
4.2M sh · $14.75M
Orbimed Advisors LLC
3.1M sh · $1.75M
Tcg Crossover Management, LLC
2.7M sh · $9.5M
Stempoint Capital LP
2.5M sh · $7.75M
Nantahala Capital Management, LLC
2.0M sh · $7.02M
Vanguard Group Inc
1.8M sh · $1.21M
Commodore Capital LP
1.6M sh · $5.59M
Adar1 Capital Management, LLC
751.1K sh · $429.28K
Ikarian Capital, LLC
620.9K sh · $2.2M
Acadian Asset Management LLC
589.7K sh · $336K
Soleus Capital Management, L.P.
550.0K sh · $1.95M
Jane Street Group, LLC
527.1K sh · $348.9K

RATINGS SNAPSHOT

Overall rating: B

DCFROEROAD/EP/EP/B
Discounted Cash Flow5
Return On Equity1
Return On Assets1
Debt To Equity4
Price To Earnings1
Price To Book5
Overall Score3

INSIDER TRADES

★
DIRECTOR
Williamson Douglas J
Purchase · 40.8K shares
2026-07-29
★
Williamson Douglas J
— · —
2026-07-29
★
OFFICER: CHIEF LEGAL OFFICER
Adler Reid G.
Purchase · 36.8K shares
2026-06-30
★
OFFICER: CHIEF FINANCIAL OFFICER
Tressler Nick B.
Purchase · 11.7K shares
2026-06-30

MOST RECENT ANALYST GRADES

GRADE SUMMARY
HOLD 2
MARKET PERFORM 1
3 GRADES IN THE LAST 12 MONTHS
Jefferies HOLD Maxim Group HOLD William Blair MARKET PERFORM

SECTORS PEERS

PEERPRICE
AGEN$7.66COMPARE
IRD$3.69COMPARE
ABOS$2.92COMPARE
HURA$2.11COMPARE
SEER$1.98COMPARE
CGTX$1.02COMPARE
INO$1.29COMPARE
SPRO$1.20COMPARE